Your 2022 wildcard predictions revealed
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
EU steers clear of Aduhelm as a bigger headache threatens
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
Lilly takes it to Biogen, and the Alzheimer’s events stack up
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.
Incyte and Seagen face tricky launches
Black box warnings could limit the sales of their newly approved therapeutics.
Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
